Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6130015 | 0.89 | CYP1A2 (0.63) | CYP1A2ALDH1A1TSHRLMNAMAPK1 | |
| SCHEMBL2591473 | 0.85 | ALDH1A1 (0.49) | CYP1A2ALDH1A1TSHRLMNAMAPK1 | |
| SCHEMBL16346393 | 0.83 | CYP1A2 (0.61) | CYP1A2ALDH1A1HSD17B10LMNAMAPK1 | |
| SCHEMBL2589313 | 0.81 | KDM4E (0.56) | CYP1A2ALDH1A1TSHRHSD17B10LMNA | |
| SCHEMBL31058796 | 0.81 | ALDH1A1 (0.59) | CYP1A2ALDH1A1TSHRLMNAMAPK1 | |
| SCHEMBL23120091 | 0.80 | CYP1A2 (0.57) | CYP1A2ALDH1A1HSD17B10LMNAMAPK1 | |
| SCHEMBL29595506 | 0.80 | CYP1A2 (0.57) | CYP1A2ALDH1A1HSD17B10LMNAMAPK1 | |
| SCHEMBL12055882 | 0.79 | ALDH1A1 (0.58) | CYP1A2ALDH1A1TSHRLMNAMAPK1 | |
| SCHEMBL30732408 | 0.79 | ALDH1A1 (0.58) | CYP1A2ALDH1A1TSHRLMNAMAPK1 | |
| 2-Aminopyridine SCHEMBL27827655 | 0.78 | NOS3 (0.61) | CYP1A2ALDH1A1HSD17B10NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10178875-B2 | Methods of modifying or imparting taste using organic compounds | GIVAUDAN S.A. (CH) | 2019-01-15 | — | — | US | disclosed |
| US-20160366922-A1 | ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2016-12-22 | — | — | US | disclosed |
| US-20160366922-A1 | ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2016-12-22 | — | — | US | disclosed |
| WO-2015000900-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2015-01-08 | — | — | WO | disclosed |
| WO-2011138266-A1 | INDOLIZINE AND IMIDAZOPYRIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011138266-A1 | INDOLIZINE AND IMIDAZOPYRIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10178875-B2 | Methods of modifying or imparting taste using organic compounds | TAS2R8, OR10J3, TAS2R7 | CYP1A2 1741/4885ALDH1A1 1202/4885TSHR 908/4885 |
| US-20160366922-A1 | ORGANIC COMPOUNDS | OR10J3, TAS2R8, OR51E2 | CYP1A2 1076/4885ALDH1A1 1031/4885TSHR 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.